Navigation Links
ERA-EDTA Congress 2011: Late Breaking Clinical Trials II
Date:6/25/2011

PRAGUE, June 25, 2011 /PRNewswire/ --


 

The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatinleads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract no. 2509]. In the ezetimibe/simvastatin group, fewer patients reached the end point "end stage renal disease", but the difference was not significant [p = 0.41].

No improvement in cardiovascular outcome due to optimised treatment quality

Cardiovascular comorbidity in CKD patients is dramatically high. The MASTERPLAN study [abstract no. 2511] aimed to evaluate whether strict implementation of all the current treatment guidelines leads to a better cardiovascular outcome in CKD patients. The primary endpoint was a composite of myocardial infarction, stroke and cardiovascular death. Despite intensified therapy and better lab values it was not possible to significantly improve cardiovascular outcome in the intervention group.

Benefits of tacrolimus therapy with prolonged release in de novo kidney transplant patients

Various immunosuppressive drugs are available, one of these being tacrolimus (Tac). There are tacrolimus products that release their active substance immediately (Tac BID) and others that release it in a prolonged manner (Tac QD). The open-label OSAKA study [abstract no. 2505] compared these two drug forms in various doses. Tac QD led to the achievement of target blood level in more patients within the first few days after transplantation than Tac BID in an identical dose.

Which SHPT therapy should be used?

In the randomised phase IV IMPACT study [abstract no. 2519] 272 hemodialyis patients with seconday hyperparathyreoidism received either paricalcitol or cinacalcet plus low-dose vitamin D. This interim analysis showed that in the paricalcitol group 78% of patients achieved an iPTH reduction of ≥30% and 65% achieved a reduction of ≥50% whilst in the cinacalcet group the figures were 50% and 36% of patients. Concerning side effects, 4 of 69 patients developed hypercalcaemia in the paricalcitol arm, while 27 of 59 patients developed hypocalcemia in the cinacalcet arm.

For further information

http://www.eraedta2011.org/press.html

Bettina Albers
albers@albersconcept.de
+49(0)174-2165629



'/>"/>
SOURCE European Renal Association European Dialysis and Transplant Association (RDA-EDT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
2. Cubist Pharmaceuticals Applauds Congressman Gingrey for Introducing Legislation to Help Fight Superbug Infections
3. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
4. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
5. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
6. U.S. Congressman Michael Capuano to Receive "Lou Gehrig Award" from ALS TDI During Gala Event this November
7. Medical Imaging and Radiation Therapy Personnel Certification Bill Introduced in Congress
8. Oregon Homecare Providers Support Congressional Bill to Repeal Misguided Medicare Bidding Program
9. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
10. 2011 Retail Clinician Education Congress to Offer Exclusive Accreditation and Networking Opportunities for Retail Healthcare Professionals
11. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
Breaking Medicine News(10 mins):